Janux Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 8, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 8, 2024
JANX$12.76-27.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
| Page | |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 42) | 125 |
| Balance Sheets | 126 |
| Statements of Operations and Comprehensive Loss | 127 |
| Statements of Stockholders’ Equity | 128 |
| Statements of Cash Flows | 129 |
| Notes to Financial Statements | 130 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.